Immunovant Inc
IMVTHealthcare|Biotechnology|USA
$39.71
-1.38 (-3.36%)
Tangible Book
$4.18
Earnings Power
$4.41
Upcoming Data Readouts (7)
Oct 2026
Est. completion
P2Subacute Cutaneous Lupus Erythematosus
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805n=56
May 2027
Est. completion
P2Graves' Disease
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT07018323n=210
Sep 2027
Est. completion
P2Rheumatoid Arthritis
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
NCT06754462n=120
Dec 2027
Est. completion
P3Generalized Myasthenia Gravis
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
NCT07039916n=231
Jun 2028
Est. completion
P2Graves' Disease
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604n=240
Jul 2028
Est. completion
P2Primary Sjögren's Syndrome
Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity
NCT06979531n=180
Aug 2028
Est. completion
P2Chronic Inflammatory Demyelinating Polyneuropathy
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662n=162
Awaiting Results (2)
Trials past primary completion date but still active — data readout may be imminent.
Jan 2026
P2
To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP
NCT05581199Jan 2025
P3
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
NCT05403541